Renin-angiotensin and kallikrein-kinin systems in diabetic renal damage

Rajko  Igić

doi:10.2298/VSP190820079I

Rajko Igić John Stroger Hospital of Cook County, Department of Anesthesiology and Pain Management, Chicago, Illinois, USA; University of Banja Luka, Faculty of Medicine, Banja Luka, Republic of Srpska, Bosnia and Herzegovina; Medical Center, Sombor, Serbia

DOI: https://doi.org/10.2298/VSP190820079I

Keywords: diabetic nephropathies, hypertension, angiotensin-converting enzyme inhibitors, angiotensin receptors antagonists, treatment outcome

References

REFERENCES

Erdös EG. Hypotensive peptides: bradykinin, kallidin, and ele-doisin. In: Garattini S, Shore PA, editors. Advances in Pharma-cology. New York: Academic Press; 1966; 4: 1–90.

Yang HY, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970; 214(2): 374–6.

Igić R, Sorrells K, Nakajima T, Erdös EG. Identity of kininase II with an angiotensin I converting enzyme. In: Back N,Sicuteri F, editors. Vasopeptides. New York: Plenum Press; 1972. p. 149–53.

Igić R. An exploration of bioactive peptides: My collaboration with Ervin G. Erdös. J Biol Chem 2018; 293(21): 7907–15.

Škrbić R, Igić R. Seven decades of angiotensin (1939-2009). Pep¬tides 2009; 30(10): 1945–50.

Ferrão FM, Lara LS, Lowe J. Renin-angiotensin system in the kid¬ney: What is new? World J Nephrol 2014; 3(3): 64–76.

Metzger R, Franke FE, Bohle RM, Alhenc-Gelas F, Danilov SM. Het¬erogeneous distribution of angiotensin I-converting en-zyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity. Microvasc Res 2011; 81(2): 206–15.

Alexiou T, Boon WM, Denton DA, Nicolantonio RD, Walker LL, McKinley MJ, et al. Angiotensinogen and angiotensin-convert-ing enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J Hypertens 2005; 23(5): 945–54.

Seki T, Miwa I, Nakajima T, Erdös EG. Plasma kallikrein-kinin system in nonmammalian blood: evolutionary aspects. Am J Physiol 1973; 224(6): 1425–30.

Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdös EG. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem 2002; 277(19): 16847–52.

Igić R. Four decades of ocular renin-angiotensin and kallikrein-kinin systems (1977-2017). Exp Eye Res 2018; 166: 74–83.

Chan GC, Tang SC. Diabetic nephropathy: landmark clinical tri¬als and tribulations. Nephrol Dial Transplant 2016; 31(3): 359–68.

Chawla T, Sharma D, Singh A. Role of the renin angiotensin sys¬tem in diabetic nephropathy. World J Diabetes 2010; 1(5): 141–5.

Alhenc-Gelas F, Bouby N, Girolami JP. Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication. Front Med (Lausanne) 2019; 6: 136.

Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witte-man JC. ACE polymorphisms. Circ Res 2006; 98(9): 1123–33.

Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. Diabetes 1994; 43(5): 690–5.

Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, et al. Contribution of genetic polymorphism in the renin-an¬giotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997; 99(7): 1585–95.

Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996; 313(7057): 591–4.

Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 2005; 54(4): 1238–44.

Costacou T, Chang Y, Ferrell RE, Orchard TJ. Identifying genetic susceptibilities to diabetes-related complications among indi-viduals at low risk of complications: An application of tree-structured survival analysis. Am J Epidemiol 2006; 164(9): 862–72.

Azizi M, Ménard J. Combined blockade of the renin-angio-tensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109(21): 2492–9.

Regoli D, Gobeil F Jr. Critical insights into the beneficial and pro¬tective actions of the kallikrein-kinin system. Vascul Phar-macol 2015; 64: 1–10.

Tomita H, Sanford RB, Smithies O, Kakoki M. The kallikrein-kinin system in diabetic nephropathy. Kidney Int 2012; 81(8): 733–44.

Bélanger S, Bovenzi V, Côté J, Neugebauer W, Amblard M, Martinez J, et al. Structure-activity relationships of novel peptide ago¬nistsof the human bradykinin B2 receptor. Peptides 2009; 30(4): 777–87.

Côté J, Savard M, Bovenzi V, Bélanger S, Morin J, Neugebauer W, et al. Novel kinin B1 receptor agonists with improved pharma¬cological profiles. Peptides 2009; 30(4): 788–95.

Devetzi M, Goulielmaki M, Khoury N, Spandidos DA, Sotiropoulou G, Christodoulou I, et al. Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein KLK1)‑based targeted therapy (Review). Int J Mol Med 2018; 41(3): 1177–86.